ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 303,28
0,66%
Dow Jones
44 938,35
0,52%
DAX
20 232,14
0,98%
Brent Oil
72,445
-1,58%
Bitcoin
96 709,81
0,76%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Celldex Therapeutics Inc (CLDX) Cours

Celldex Therapeutics Inc

Celldex Therapeutics Inc (CLDX)

NASDAQ
27,12
0,90
( 3,43% )
Mis à jour : 20:04:07
Retardé de 15 minutes

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Statistiques et détails clés

Dernier
27,12
Prix Achat
27,09
Prix Vente
27,13
Volume échangé
345 254
26,19 Fourchette du Jour 28,65
22,9291 Plage de 52 semaines 53,18
Cap du marché
1,799B
Clôture Veille
26,22
Ouverture
26,28
Dernière Transaction
2
@
27.1136
Dernière heure de transaction
20:05:01
Volume financier
US$ 9 601 638
VWAP
27,8104
Volume moyen (3 m)
1 197 305
Actions en circulation
66 344 236
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-12,86
Bénéfice par action (BPA)
-2,13
Chiffre d'affairess
6,88M
Bénéfice net
-141,43M

À propos de Celldex Therapeutics Inc

Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung c... Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527. Show more

Secteur
In Vitro,in Vivo Diagnostics
Industrie
In Vitro,in Vivo Diagnostics
Site Web
www.celldex.com
Siège social
Wilmington, Delaware, USA
Fondé
-
Celldex Therapeutics Inc est coté dans le secteur In Vitro,in Vivo Diagnostics de la NASDAQ avec le ticker CLDX. Le dernier cours de clôture d'Celldex Therapeutics était de US$26,22. Au cours de la dernière année, les actions de Celldex Therapeutics ont été négociées dans une fourchette de prix de US$ 22,9291 à US$ 53,18.

Celldex Therapeutics compte actuellement 66 344 236 actions en circulation. La capitalisation boursière d'Celldex Therapeutics est de US$1,74 milliard. Celldex Therapeutics a un ratio cours/bénéfice (ratio PE) de -12.86.

CLDX Dernières nouvelles

Plus de nouvelles

Form 4 - Statement of changes in beneficial ownership of securities

20 Novembre 2024
Edgar (US Regulatory)

Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases

HAMPTON, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in the Company’s Phase 1a study of CDX-622 in...

20 Novembre 2024
GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

15 Novembre 2024
Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

14 Novembre 2024
Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

14 Novembre 2024
Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

14 Novembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

12 Novembre 2024
Edgar (US Regulatory)

Celldex Therapeutics to Present at Upcoming Investor Conferences

HAMPTON, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences:...

11 Novembre 2024
GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

08 Novembre 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

06 Novembre 2024
Edgar (US Regulatory)
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10.130.48165987402726.9928.6526.1964927727.3148007CS
41.124.307692307692628.6522.9291105168626.40709441CS
12-14.67-35.10409188841.794722.9291119730531.09518171CS
26-5.77-17.54332623932.894722.929192685433.54265591CS
52-5.03-15.645412130632.1553.1822.929185435836.93765176CS
156-8.78-24.456824512535.953.1819.8567796934.27669293CS
26024.58967.7165354332.5457.21.576434826.49704667CS

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
CYCNCyclerion Therapeutics Inc
US$ 7,30
(353,42%)
114,91M
SMXSMX Security Matters Public Company
US$ 0,5322
(173,20%)
486,26M
CNEYCN Energy Group Inc
US$ 0,5802
(83,84%)
149,36M
SRMSRM Entertainment Inc
US$ 1,1301
(79,35%)
132,23M
HTOOFusion Fuel Green PLC
US$ 0,5351
(68,27%)
268,77M
RLMDRelmada Therapeutics Inc
US$ 0,639249
(-76,92%)
14,24M
MIGIMawson Infrastructure Group Inc
US$ 0,8672
(-54,60%)
11,19M
MONDMondee Holdings Inc
US$ 0,2005
(-32,06%)
2,65M
ORISOriental Rise Holdings Ltd
US$ 8,45
(-29,29%)
511,31k
FGLFounder Group Limited
US$ 2,945
(-27,82%)
9,79M
SMXSMX Security Matters Public Company
US$ 0,5322
(173,20%)
486,42M
SVMHSRIVARU Holding Ltd
US$ 0,02715
(23,41%)
437,75M
HTOOFusion Fuel Green PLC
US$ 0,535
(68,24%)
268,78M
CNEYCN Energy Group Inc
US$ 0,5802
(83,84%)
149,36M
SRMSRM Entertainment Inc
US$ 1,1301
(79,35%)
132,23M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
CLDX
Celldex Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés